Turning Point Therapeutics：Turning Point Therapeutics
Turning Point Therapeutics
Aprecisiononcologycompany,driventodeveloptherapiesthatmarkaturningpointforpatients.·檢舉公司·關閉選單.。其他文章還包含有：「BristolMyersSquibbtoAcquireTurningPointTherapeutics...」、「BMS重砸41億美金收購TurningPointTherapeutics」、「TurningPointTherapeutics」、「BristolMyersSquibbCompletesAcquisitionofTurning...」、「BMSstrikesupRocherivalrywith$4.1BTurningPointbuy」、「Repotrectinib」
查看更多 離開網站
Bristol Myers Squibb to Acquire Turning Point Therapeutics ...
https://news.bms.com
The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated ...
BMS 重砸41億美金收購Turning Point Therapeutics
https://news.gbimonthly.com
反應持續時間從1.4 至35.1 個月。BMS 在收購公告中表示，這樣的反應持續時間，都比目前NSCLC 一線治療藥物中，可取得的ROS1藥物所能達到的持續時間更長。
Turning Point Therapeutics
https://www.moneydj.com
Turning Point Therapeutics, Inc.(TPTX.US)為一家臨床階段的生物製藥公司，設計及開發新型小分子腫瘤標靶療法，藉以解決現有療法的關鍵限制。
Bristol Myers Squibb Completes Acquisition of Turning ...
https://news.bms.com
NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning ...
BMS strikes up Roche rivalry with $4.1B Turning Point buy
https://www.fiercebiotech.com
Eyeing a rivalry with Roche and a new cancer asset slated to hit the markets next year, Bristol Myers is picking up Turning Point Therapeutics
Repotrectinib
https://drughunter.com
Turning Point Therapeutics ($TPTX) was recently acquired by BMS for a whopping $4.1 billion in cash. Turning Point's most advanced molecule.